Hypertriglyceridaemia and risk of coronary artery disease (Q39181612)

9 September 2017

title

Hypertriglyceridaemia and risk of coronary artery disease (English)

1 reference

9 September 2017

Željko Reiner

1

1 reference

9 September 2017

language of work or name

English

0 references

publication date

16 March 2017

1 reference

Nature Reviews Cardiology

9 September 2017

published in

1 reference

9 September 2017

volume

14

1 reference

9 September 2017

issue

7

1 reference

9 September 2017

page(s)

401-411

1 reference

Statins in the primary prevention of cardiovascular disease

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Dyslipidemias in the prevention of cardiovascular disease: risks and causality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Management of patients with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Lipoprotein lipase: from gene to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Apolipoprotein C-III: From Pathophysiology to Pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Dysfunctional HDL and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 middle aged males: interaction with serum cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Plasma triglyceride level and mortality from coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglycerides and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: Cohort Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Common variants associated with plasma triglycerides and risk for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Mendelian randomization of blood lipids for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Vascular Disease Risk in Patients With Hypertriglyceridemia: Endothelial Progenitor Cells, Oxidative Stress, Accelerated Senescence, and Impaired Vascular Repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Relationship between serum triglyceride levels and endothelial function in a large community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglycerides are a predictive factor for arterial stiffness: a community-based 4.8-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Postprandial hypertriglyceridemia as a coronary risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Weight loss and improvement of lipid profiles in morbidly obese patients after laparoscopic one-anastomosis gastric bypass: 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Dietary carbohydrate: relationship to cardiovascular disease and disorders of carbohydrate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Combination lipid therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Adverse effects of statins - myths and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Icosapent ethyl for treatment of elevated triglyceride levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Gene therapy for lipoprotein lipase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglyceride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Inactivation of lipoprotein lipase occurs on the surface of THP-1 macrophages where oligomers of angiopoietin-like protein 4 are formed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Combined therapy in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Trends in lipids and lipoproteins in US adults, 1988-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the E

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese Multi-provincial Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRCARDIO.2017.31

LDL and HDL enriched in triglyceride promote abnormal cholesterol transport.

31 March 2020

1 reference

12 December 2020

Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV

1 reference

12 December 2020

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

1 reference

12 December 2020

Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2017.31

1 reference

Dimensions Publication ID

9 September 2017

1084129577

0 references

Fatcat ID

release_ghcqp2qhmbactpr2jl32nr7ccu

0 references

1 reference